JP2016515516A5 - - Google Patents

Info

Publication number

JP2016515516A5

JP2016515516A5 JP2016502812A JP2016502812A JP2016515516A5 JP 2016515516 A5 JP2016515516 A5 JP 2016515516A5 JP 2016502812 A JP2016502812 A JP 2016502812A JP 2016502812 A JP2016502812 A JP 2016502812A JP 2016515516 A5 JP2016515516 A5 JP 2016515516A5

Authority

JP

Japan

Prior art keywords

item

seq

composition

polypeptide

amino acid

Prior art date

2014-03-14

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 108090000765 processed proteins & peptides Proteins 0.000 claims description 136
• 229920001184 polypeptide Polymers 0.000 claims description 120
• 102000004196 processed proteins & peptides Human genes 0.000 claims description 120
• 125000003275 alpha amino acid group Chemical group 0.000 claims description 40
• 201000003984 candidiasis Diseases 0.000 claims description 38
• 239000000203 mixture Substances 0.000 claims description 36
• 241000222122 Candida albicans Species 0.000 claims description 30
• 206010007134 Candida infections Diseases 0.000 claims description 25
• 241000124008 Mammalia Species 0.000 claims description 23
• 206010042938 Systemic candida Diseases 0.000 claims description 13
• 208000019164 disseminated candidiasis Diseases 0.000 claims description 13
• 241000894006 Bacteria Species 0.000 claims description 9
• 238000007918 intramuscular administration Methods 0.000 claims description 9
• 241000222178 Candida tropicalis Species 0.000 claims description 5
• 241000235645 Pichia kudriavzevii Species 0.000 claims description 5
• 241000222126 [Candida] glabrata Species 0.000 claims description 5
• 239000002671 adjuvant Substances 0.000 claims description 5
• 229940095731 candida albicans Drugs 0.000 claims description 5
• 208000032343 candida glabrata infection Diseases 0.000 claims description 5
• 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
• 238000007920 subcutaneous administration Methods 0.000 claims description 5
• 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 4
• 241000222173 Candida parapsilosis Species 0.000 claims description 4
• 229940055022 candida parapsilosis Drugs 0.000 claims description 4
• 230000028993 immune response Effects 0.000 claims description 4
• 239000008280 blood Substances 0.000 claims description 3
• 210000004369 blood Anatomy 0.000 claims description 3
• 241000589291 Acinetobacter Species 0.000 claims description 2
• 239000003085 diluting agent Substances 0.000 claims description 2
• 239000003937 drug carrier Substances 0.000 claims description 2
• 230000001939 inductive effect Effects 0.000 claims description 2
• 241000191967 Staphylococcus aureus Species 0.000 claims 2
• 238000000034 method Methods 0.000 description 32
• 229960005486 vaccine Drugs 0.000 description 17
• FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 16
• 230000004927 fusion Effects 0.000 description 9
• 150000007523 nucleic acids Chemical class 0.000 description 9
• 108020004707 nucleic acids Proteins 0.000 description 8
• 102000039446 nucleic acids Human genes 0.000 description 8
• 240000004808 Saccharomyces cerevisiae Species 0.000 description 7
• 239000008194 pharmaceutical composition Substances 0.000 description 7
• 241000700605 Viruses Species 0.000 description 6
• 230000003053 immunization Effects 0.000 description 3
• PCTMTFRHKVHKIS-BMFZQQSSSA-N (1s,3r,4e,6e,8e,10e,12e,14e,16e,18s,19r,20r,21s,25r,27r,30r,31r,33s,35r,37s,38r)-3-[(2r,3s,4s,5s,6r)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,30,31,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10 Chemical compound C1C=C2C[C@@H](OS(O)(=O)=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2.O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 PCTMTFRHKVHKIS-BMFZQQSSSA-N 0.000 description 2
• 125000002842 L-seryl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])O[H] 0.000 description 2
• 239000000427 antigen Substances 0.000 description 2
• 230000000890 antigenic effect Effects 0.000 description 2
• 102000036639 antigens Human genes 0.000 description 2
• 108091007433 antigens Proteins 0.000 description 2
• 238000012258 culturing Methods 0.000 description 2
• 108020001507 fusion proteins Proteins 0.000 description 2
• 102000037865 fusion proteins Human genes 0.000 description 2
• 208000013210 hematogenous Diseases 0.000 description 2
• 238000002649 immunization Methods 0.000 description 2
• 238000004519 manufacturing process Methods 0.000 description 2
• 238000002255 vaccination Methods 0.000 description 2
• 241000588724 Escherichia coli Species 0.000 description 1
• 108091028043 Nucleic acid sequence Proteins 0.000 description 1
• 206010041925 Staphylococcal infections Diseases 0.000 description 1
• 230000002209 hydrophobic effect Effects 0.000 description 1
• 230000002163 immunogen Effects 0.000 description 1
• 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 description 1